Table 1 Mutational burden in NXS2 vs 9464D-GD2 cells. Genomic analysis of tumor cell lines reveals that the 9464D and 9464D-GD2 neuroblastoma cell lines have lower mutation burdens compared to the NXS2 neuroblastoma cell line. All 3 lines show TP53 mutations

From: Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition